Gliotoxin

Gliotoxin

SCHEMBL54420

CN1C(=O)[C@]23CC4=CC=C[C@H](O)[C@H]4N2C(=O)[C@@]1(CO)SS3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 11/20 1.00
SUV39H1 O43463 3/20 1.00
PKM P14618 1/20 1.00
FNTA P49354 1/20 1.00
FNTB P49356 1/20 1.00
PGGT1B P53609 1/20 1.00
RNF31 Q96EP0 1/20 1.00
RBCK1 Q9BYM8 1/20 1.00
SHARPIN Q9H0F6 1/20 1.00
EP300 Q09472 6/20 0.45
HIF1A Q16665 5/20 0.45
NSD2 O96028 2/20 0.45
TXNRD1 Q16881 1/20 0.45
NSD1 Q96L73 1/20 0.45
NSD3 Q9BZ95 1/20 0.45
CREBBP Q92793 2/20 0.40
HKDC1 Q2TB90 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gliotoxin SCHEMBL4294337 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL9667270 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL12149513 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL14514067 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL13341245 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL12018743 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL12618354 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL14579856 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL14986985 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL20199940 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4862 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
EP-4719451-A2 METHODS FOR TREATING IGF-1R-RELATED CANCERS WITH AN INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO A CYTOTOXIC AGENT Lirum Therapeutics, Inc. (US) 2026-04-08 EP claimed
EP-4719455-A2 METHODS FOR TREATING IGF-1R-RELATED PEDIATRIC CANCERS WITH AN INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO A CYTOTOXIC AGENT Lirum Therapeutics, Inc. (US) 2026-04-08 EP claimed
CN-121586579-A Methods for treating IGF-1R-related cancers with insulin-like growth factor 1 receptor ligands conjugated to cytotoxic agents 利鲁姆治疗公司 2026-02-27 CN claimed
WO-2026043908-A1 COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS ALLTECH, INC. (US) 2026-02-26 WO claimed
US-12527781-B2 Treatment of neurodegenerative conditions by disruption of Rhes THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-20 US claimed
US-20250367267-A1 TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT LIRUM THERAPEUTICS INC (US) 2025-12-04 US claimed
EP-4637348-A1 DOUBLE ENCAPSULATED NANOCOMPOSITE FOR STAGED DELIVERY OF ACTIVE INGREDIENT(S), AND A METHOD OF PRODUCING THEREOF Council Of Scientific & Industrial Research (IN) 2025-10-29 EP claimed
US-20250319179-A1 MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY NOVARTIS AG (CH) 2025-10-16 US claimed
EP-4605563-A2 METHOD FOR REDUCING PLANT STRESS, FUNGI, AND MYCOTOXINS Universidad Politécnica de Madrid (ES) 2025-08-27 EP claimed
EP-0767799-A1 A 24 KILODALTON CYTOPLASMIC PROTEASE ACTIVATING DNA FRAGMENTATION APOPTOSIS PANORAMA RESEARCH, INC. (US) 1997-04-16 EP claimed
US-5605826-A PREPARING CYTOPLASMIC EXTRACT OF MAMMALIAN CELLS PRETREATED WITH APOPTOSIS INDUCING AGENT, ISOLATING PROTEASE USING AFFINITY COLUMN HAVING IMMOBILIZED PROTEASE INHIBITOR, PURIFYING APOPTOTIC PROTEASE USING HEPARIN-SEPHAROSE COLUMN PANORAMA RESEARCH, INC. (US) 1997-02-25 US claimed
WO-1996014746-A1 A METHOD OF INDUCING RESISTANCE TO TUMOR GROWTH THOMAS JEFFERSON UNIVERSITY (US) 1996-05-23 WO claimed
WO-1995034576-A1 A 24 KILODALTON CYTOPLASMIC PROTEASE ACTIVATING DNA FRAGMENTATION APOPTOSIS PANORAMA RESEARCH, INC. (US) 1995-12-21 WO claimed
US-5268173-A Fungicide culture product THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES SECRETARY OF AGRICULTURE (US) 1993-12-07 US claimed
WO-1992010198-A1 IMMUNOTHERAPEUTIC AGENTS, COMPOSITIONS AND METHODS JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) 1992-06-25 WO claimed
EP-0163475-B1 IMMUNOREGULATION THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1992-01-08 EP claimed
US-4886796-A EPIPOLYTHIODIOXOPIPERAZINE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1989-12-12 US claimed
US-4727018-A PRETREATMENT WITH EPIPOLYTHIODIOXOPIPERAZINES AUSTRALIAN NATIONAL UNIVERSITY, OF ACTON, THE (AU) 1988-02-23 US claimed
EP-0163475-A2 Immunoregulation THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1985-12-04 EP claimed